The telehealth company Hims & Hers, known for its weight-loss offerings, now grapples with investor concerns centered on its dependence on compounded GLP-1 agonist drugs. Legal and regulatory uncertainties in this segment threaten long-term viability, especially as original manufacturers defend their market dominance.
New Antitrust Lawsuit Targets GLP-1 Giants
On January 14, 2026, Strive Specialties Inc. filed an antitrust lawsuit against Eli Lilly and Novo Nordisk. The complaint alleges anti-competitive practices aimed at preventing telehealth providers and pharmacies from offering compounded versions of blockbuster GLP-1 drugs like Mounjaro (tirzepatide) and Wegovy (semaglutide).
Although Hims & Hers is not named as a defendant, its growth heavily relies on this market. The case highlights intense competition in the GLP-1 weight loss space and signals aggressive patent protection efforts by pharmaceutical leaders.
Regulatory Risks for Compounded GLP-1s
- If supply shortages of branded drugs like Wegovy and Ozempic resolve, FDA exemptions for pharmacy compounding may end.
- Tighter regulations could limit access to lower-cost compounded alternatives.
- This directly affects telehealth models dependent on compounded semaglutide and tirzepatide for weight management.
Analyst Perspectives on GLP-1 Dependencies
Bank of America maintains an "Underperform" rating, warning that 2026 revenue and margin estimates appear optimistic amid rising investments.
Precision tracking for your journey
Join thousands using Shotlee to accurately track GLP-1 medications and side effects.
📱 Get the Shotlee App
Track your GLP-1 medications, peptides, and health metrics on the go with our mobile app!
Evercore ISI started coverage with an "In Line" rating, indicating limited short-term potential. These views reflect broader caution around compounded GLP-1 sustainability.
Implications for GLP-1 Access and Weight Management
The market views compounded GLP-1s as a high-risk segment. One scenario preserves regulatory allowances for continued expansion; the other enforces stricter patent rules, curbing supply.
The Strive lawsuit underscores big pharma's resolve to protect the multi-billion-dollar weight-loss market. For patients seeking GLP-1 medications, this could reshape availability through telehealth platforms.
Upcoming quarterly reports will clarify Hims & Hers' navigation of these GLP-1 legal challenges, potentially influencing future access to peptide-based weight therapies.
